Testing the safest dose for a prostate cancer drug
Part of Cancer, Kidney & urinary clinical trials.
This early-phase trial (Phase 1) tests the safest dose of BP-C2 in people with prostate cancer who are on hormone treatment. It’s mainly designed to check safety and how the body handles the medicine, which could help future treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 80 years old and have prostate cancer
- Be currently receiving hormone treatment
- Have an expected survival of at least 3 months
- Have liver and kidney blood tests in acceptable ranges (not severely abnormal)
- Not have brain metastases or certain other active cancers at the same time
- You must be able to understand the study, and give written consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (BMS-986365) combined with another hormone therapy (degarelix) before radical prostatectomy for high-risk prostate cancer. The goal is to see if this combination helps lower cancer activity before surgery.
This Phase 3 study compares an immediate curative treatment plan versus a more conservative approach in men age 75 and older with newly diagnosed, high-risk prostate cancer. The goal is to see which strategy controls the cancer while better protecting quality of life.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
This trial studies a treatment that targets a protein called PSMA in people with prostate cancer. It may help shrink or control the cancer and is being tested in different risk groups and stages of disease.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.